Skip to main content
OpenTrials
Completed

NCT Number: NCT04053959

Artificial Intelligence Assisted Insulin Titration System

This is a single-center, open-labeled, parallel group, randomized controlled trial to access the effect and safety of the Artificial Intelligence Assisted Insulin Titration System in patients with Type 2 Diabetes Mellitus.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

180 Fenglin Road

Shanghai, 200032, China

About this study

The study enrolls 44 patients with Type 2 Diabetes in Zhongshan Hospital who are on treatment with insulin for at least 3 months. They are randomly allocated into 2 groups at a ratio of 1:1 after screening for the inclusion and exclusion criteria. Patients in the Intervention group receive insulin regimen set by the AI assisted system and patients in Control group receive insulin regimen set by physicians. This study will be conducted in the Department of Endocrinology, Zhongshan Hospital,Fudan University and consist of a 7-day intervention period. Patient allocation will be stratified by HbA1c, BMI and previous total insulin doses.The primary endpoint is the percentage of time of sensor glucose measurements in targeted range (3.9-10 mmol/L) during the 7-days trial period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women aged 18-75 years old;
  • Subjects who had been diagnosed with type 2 diabetes;
  • Subjects who are on treatment with insulin for at least 3 months;
  • HbA1c: 7.0%-11.0%.

Exclusion criteria

  • Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic hyperosmolar state;
  • Subjects who change the insulin regimens during hospitalization;
  • BMI ≥ 45kg/m2;
  • Women who are pregnant or nursing;
  • Subjects with severe cardiac, hepatic, renal or general diseases;
  • Subjects with psychiatric disorders or impaired cognitive function;
  • Subjects with severe edema, infections or peripheral circulation disorders;
  • Patients treated with surgery during hospitalization;
  • Subjects that are, in the judgement of the investigator, unlikely to comply with the protocol.

Treatment and study plan

AI assisted insulin system

Drug

The patients receive the insulin regime set by AI assisted insulin titration system

Physician based insulin regime

Drug

Patients receive the insulin regime recommended by physicians

Primary outcomes

  1. Proportion of time in target range

    Time frame: During 7-day intervention

    The well-controlled blood glucose level is defined as the time of sensor glucose measurements in targeted range (3.9-10 mmol/L)

Secondary outcomes

  1. Proportion of time in which the blood glucose level is over 10 mmol/L

    Time frame: During 7-day intervention

    The poor control of blood glucose level is defined as greater than 10 mmol/L

  2. Proportion of time in which the blood glucose level is below 3.9 mmol/L

    Time frame: During 7-day intervention

    The hypoglycemia is defined as blood glucose level less than 3.9mmol/L

  3. Total insulin dose

    Time frame: Each day during 7-day intervention

    The total insulin dose is defined as daily insulin dose

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Official study title

A Study to Assess the Effect and Safety of Artificial Intelligence Assisted Insulin Titration System on Glucose Control in Type 2 Diabetes Mellitus Patients: A Single-center, Open-labeled, Parallel, Randomized Controlled Trial

Acronym: iNCDSS

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Aug 13, 2019
Registry last updated
Jul 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.